



**Contacts:**

**TONIX Pharmaceuticals Holdings Corp.**  
Benjamin Selzer, Chief Operating Officer  
(212) 980-9155

**Porter, LeVay & Rose, Inc.**  
Sharon Weinstein, Investor Relations  
Bill Gordon, Media Relations  
(212) 564-4700

**FOR IMMEDIATE RELEASE**

**TONIX PHARMACEUTICALS TO PRESENT AT BIOTECH SHOWCASE AND ONEMEDFORUM CONFERENCES IN  
SAN FRANCISCO ON JANUARY 9 AND 10, 2012**

**New York, NY – January 4, 2012** – Tonix Pharmaceuticals Holding Corp. (OTCBB:TNXP) (“TONIX”), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system (“CNS”), including fibromyalgia syndrome (“FM”) and post-traumatic stress disorder (“PTSD”), will be presenting at two conferences in San Francisco in January 2012. On Monday, January 9, 2012 at 10:00 a.m. PST, TONIX’s presentation at the Biotech Showcase 2012 will take place, and on Tuesday, January 10, 2012 at 10:15 a.m. PST, TONIX will present at the OneMedForum Conference.

Seth Lederman, M.D., Chairman and President of TONIX, will provide an overview of the company and discuss its clinical development and business strategy. Each of the presentations will be webcast, and can be accessed at the following links:

OneMed Forum: [www.onemedplace.com](http://www.onemedplace.com)  
Biotech Showcase: <http://www.media-server.com/m/p/422u9mik>

Members of the investment community who are interested in meeting with management during the week of January 9 in San Francisco, are encouraged to call Sharon Weinstein at 212-564-4700 to schedule a meeting.

**About TONIX Pharmaceuticals**

TONIX Pharmaceuticals is developing new therapies for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX reformulates approved pharmaceutical active ingredients to design products with optimal safety, efficacy and predictability. Its most advanced product candidates, TNX-102 for FM and TNX-105 for PTSD, are novel dosage formulation of cyclobenzaprine, the active ingredient in two U.S. FDA-approved muscle relaxants. To learn more about the Company and its pipeline of treatments for CNS conditions, please visit [www.tonixpharma.com](http://www.tonixpharma.com).

*Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on TONIX's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. TONIX does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Current Report on Form 8-K filed with the SEC on October 14, 2011 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.*

###